DiGeorge Syndrome Drug Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Global Prevalence of the DiGeorge Syndrome to Drive the Market Growth
- Increasing R&D Activities for the Development of Better Drugs and Treatment Methods to boost the Market Growth.
Challenges
- High Cost of the DiGeorge Syndrome Drugs to Hamper Market Growth
- Increased Circulation of Generic Drugs in the Market and Lack of Awareness Regarding the Disease likely to Challenge the Market Growth
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
DiGeorge Syndrome Drug Market size is set to register remarkable growth rate during the forecast period i.e., between 2025-2037.
The market growth is driven by growing patient pool of the disease and the need for treatment for the wide range of symptoms caused by this genetic disorder.
North America industry is set to account for largest revenue share by 2037, on the back of rising prevalence of the disorder.
The major players in the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Cerecor, Inc., Bausch Health Companies Inc., Natera, Inc, Boehringer Ingelheim International GmbH, AbbVie Inc., Amgen Inc., Novartis AG and Progenity, Inc., among others.
